Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients.
Biomarker
COVID-19
Calprotectin
Dynamics
S100A8/A9
Serial measurement
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
18
02
2022
revised:
26
04
2022
accepted:
10
05
2022
pubmed:
2
6
2022
medline:
15
6
2022
entrez:
1
6
2022
Statut:
ppublish
Résumé
Severe COVID-19 is associated with a high circulating level of calprotectin, the S100A8/S100A9 alarmin heterodimer. Baseline calprotectin amount measured in peripheral blood at diagnosis correlates with disease severity. The optimal use of this biomarker along COVID-19 course remains to be delineated. We focused on patients with a WHO-defined moderate COVID-19 requiring hospitalization in a medical ward. We collected plasma and serum from three independent cohorts (N = 626 patients) and measured calprotectin amount at admission. We performed longitudinal measures of calprotectin in 457 of these patients (1461 samples) and used a joint latent class mixture model in which classes were defined by age, body mass index and comorbidities to identify calprotectin trajectories predicting the risk of transfer into an intensive care unit or death. After adjustment for age, sex, body mass index and comorbidities, the predictive value of baseline calprotectin in patients with moderate COVID19 could be refined by serial monitoring of the biomarker. We discriminated three calprotectin trajectories associated with low, moderate, and high risk of poor outcome, and we designed an algorithm available as online software (https://calpla.gustaveroussy.fr:8443/) to monitor the probability of a poor outcome in individual patients with moderate COVID-19. These results emphasize the clinical interest of serial monitoring of calprotectin amount in the peripheral blood to anticipate the risk of poor outcomes in patients with moderate COVID-19 hospitalized in a standard care unit. The study received support (research grants) from ThermoFisher immunodiagnostics (France) and Gustave Roussy Foundation.
Sections du résumé
BACKGROUND
BACKGROUND
Severe COVID-19 is associated with a high circulating level of calprotectin, the S100A8/S100A9 alarmin heterodimer. Baseline calprotectin amount measured in peripheral blood at diagnosis correlates with disease severity. The optimal use of this biomarker along COVID-19 course remains to be delineated.
METHODS
METHODS
We focused on patients with a WHO-defined moderate COVID-19 requiring hospitalization in a medical ward. We collected plasma and serum from three independent cohorts (N = 626 patients) and measured calprotectin amount at admission. We performed longitudinal measures of calprotectin in 457 of these patients (1461 samples) and used a joint latent class mixture model in which classes were defined by age, body mass index and comorbidities to identify calprotectin trajectories predicting the risk of transfer into an intensive care unit or death.
FINDINGS
RESULTS
After adjustment for age, sex, body mass index and comorbidities, the predictive value of baseline calprotectin in patients with moderate COVID19 could be refined by serial monitoring of the biomarker. We discriminated three calprotectin trajectories associated with low, moderate, and high risk of poor outcome, and we designed an algorithm available as online software (https://calpla.gustaveroussy.fr:8443/) to monitor the probability of a poor outcome in individual patients with moderate COVID-19.
INTERPRETATION
CONCLUSIONS
These results emphasize the clinical interest of serial monitoring of calprotectin amount in the peripheral blood to anticipate the risk of poor outcomes in patients with moderate COVID-19 hospitalized in a standard care unit.
FUNDING
BACKGROUND
The study received support (research grants) from ThermoFisher immunodiagnostics (France) and Gustave Roussy Foundation.
Identifiants
pubmed: 35644124
pii: S2352-3964(22)00258-4
doi: 10.1016/j.ebiom.2022.104077
pmc: PMC9132728
pii:
doi:
Substances chimiques
Biomarkers
0
Leukocyte L1 Antigen Complex
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104077Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
Références
Virology. 2020 Jul;546:122-126
pubmed: 32452410
Nature. 2021 Nov;599(7884):283-289
pubmed: 34517409
J Immunol. 2021 Apr 1;206(7):1597-1608
pubmed: 33579725
J Rheumatol. 2015 May;42(5):760-70
pubmed: 25729036
JCI Insight. 2021 Jan 11;6(1):
pubmed: 33232303
J Clin Med. 2021 Feb 15;10(4):
pubmed: 33672040
Sci Immunol. 2021 Aug 19;6(62):
pubmed: 34413139
Cell Death Dis. 2020 Nov 6;11(11):957
pubmed: 33159040
J Infect. 2021 Apr;82(4):84-123
pubmed: 33217473
Clin Chim Acta. 2021 Jun;517:149-155
pubmed: 33689693
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
Ann Rheum Dis. 2016 Jul;75(7):1357-62
pubmed: 26698844
Cell Mol Immunol. 2020 Sep;17(9):992-994
pubmed: 32620787
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Nat Immunol. 2021 Jan;22(1):19-24
pubmed: 33208929
Brief Bioinform. 2021 Nov 5;22(6):
pubmed: 34081102
Proteomics. 2021 Jun;21(11-12):e2000278
pubmed: 33945677
J Infect. 2022 Feb;84(2):e27-e29
pubmed: 34843810
Cell Host Microbe. 2021 Feb 10;29(2):222-235.e4
pubmed: 33388094
Respir Res. 2020 Jul 6;21(1):171
pubmed: 32631317
Blood Adv. 2021 Feb 9;5(3):662-673
pubmed: 33560382
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
BMC Infect Dis. 2021 Sep 8;21(1):932
pubmed: 34496795
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
Clin Chem Lab Med. 2021 Nov 01;60(2):e57-e60
pubmed: 34714981
Cell Syst. 2021 Aug 18;12(8):780-794.e7
pubmed: 34139154
Inflamm Res. 2022 Jan;71(1):57-67
pubmed: 34718856
Sci Rep. 2021 Jan 15;11(1):1580
pubmed: 33452298